<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04829045</url>
  </required_header>
  <id_info>
    <org_study_id>NCT04829045</org_study_id>
    <secondary_id>JKEUPM-2018-294</secondary_id>
    <secondary_id>U1111-1219-3545</secondary_id>
    <nct_id>NCT04829045</nct_id>
  </id_info>
  <brief_title>Effects of Acupuncture as Adjunctive Therapy in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>The Effect of Acupuncture as Adjunctive Therapy on Homeostasis Model Assessment-insulin Resistance and Health Related Quality of Life in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Putra Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Putra Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effect of acupuncture as an adjunctive therapy on&#xD;
      homeostasis model assessment-insulin resistance (HOMA-IR) and health-related quality of life&#xD;
      (HRQoL) in patients with type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo controlled and parallel design trial.&#xD;
      Participants will be randomized to either acupuncture (n=30) or placebo (n=30) using a 1:1&#xD;
      ratio. The permuted blocks with a block size of 2 will be used. Both groups will continue&#xD;
      with their routine diabetes care. Primary outcome of HOMA-IR will be measured at the time of&#xD;
      recruitment (baseline) and after completion of 10 sessions (week 7) of the treatment.&#xD;
      Secondary outcome of HRQOL will be measured at the time of recruitment (baseline), after&#xD;
      completion of 5 sessions (week 3/4) and 10 sessions (week 7) of the treatment while outcomes&#xD;
      of body mass index and waist circumference are measured at the time of recruitment (baseline)&#xD;
      and after completion of 10 sessions (week 7) of the treatment. Any adverse event will be&#xD;
      recorded at every visit. The sequence generation and allocation will remain concealed from&#xD;
      the patient and practitioner.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting serum insulin</measure>
    <time_frame>change from baseline fasting serum insulin at 7 weeks</time_frame>
    <description>Analyzed in μU/ml using heparin tube</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>change from baseline fasting plasma glucose at 7 weeks</time_frame>
    <description>Analyzed in mmol l-^1 using sodium fluoride tube</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Homeostasis model assessment- insulin resistance (HOMA-IR)</measure>
    <time_frame>change from baseline HOMA-IR at 7 weeks</time_frame>
    <description>Fasting serum insulin and fasting plasma glucose will be combined to report HOMA-IR in unit [fasting serum insulin (μU/ml)×fasting plasma glucose (mmol l-1)/22.5](Mathews et al., 1985).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>change from baseline HRQoL at 3-4 weeks</time_frame>
    <description>Changes is assessed using World Health Organization Quality of Life Assessment: Brief Version (WHOQoL-BREF [English/Malay]) questionnaire which consists of 26 items and the scores range from 0-100. The higher the score, the better the HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (HRQoL)</measure>
    <time_frame>change from baseline HRQoL at 7 weeks</time_frame>
    <description>Changes is assessed using World Health Organization Quality of Life Assessment: Brief Version (WHOQoL-BREF [English/Malay]) questionnaire which consists of 26 items and the scores range from 0-100. The higher the score, the better the HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>change from baseline weight at 7 weeks</time_frame>
    <description>Changes is measured using digital scale TANITA weighing machine in kilograms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>change from baseline body mass index at 7 weeks</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2. Height will be measured in centimeter using SECA body meter while weight will be measured in kilograms using digital scale TANITA weighing machine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>change from baseline waist circumference at 7 weeks</time_frame>
    <description>Changes is measured using SECA measuring tape in centimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident of treatment adverse events in terms of intensity (grades 1 - 5)</measure>
    <time_frame>7 weeks</time_frame>
    <description>Evaluated according to National Cancer Institute (2017) guidelines in terms of intensity (grade 1 - 5). Higher grades mean worst adverse event.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Acupuncture</condition>
  <arm_group>
    <arm_group_label>Acupuncture plus diabetic routine care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive acupuncture treatment using press needles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus diabetic routine care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects are given placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SEIRIN PYONEX Acupuncture Needles</intervention_name>
    <description>10 press needles (PYONEX ø0.20×1.5mm made by Seirin Corporation) will be placed on abdomen area; 10 sessions over 6 weeks.</description>
    <arm_group_label>Acupuncture plus diabetic routine care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PYONEX Placebo</intervention_name>
    <description>Subjects are given placebo on abdomen area; 10 sessions over 6 weeks.</description>
    <arm_group_label>Placebo plus diabetic routine care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting plasma glucose (FPG) ≥ 7.0 mmol/L [126 mg/dL] or HbA1c ≥ 6.5%.&#xD;
&#xD;
          -  Subjects have had type 2 diabetes mellitus for more than one year&#xD;
&#xD;
          -  Receive oral anti-diabetic agents on a stable dose over the previous 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under insulin therapy&#xD;
&#xD;
          -  With other acute or chronic health problems&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 40.0 kg/m²&#xD;
&#xD;
          -  Needle phobia or allergy to adhesive plaster&#xD;
&#xD;
          -  Planning to move out from Malaysia within 4 months'&#xD;
&#xD;
          -  Being pregnant, planning for pregnancy or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheok Yean Chin, MSc, OMBAcC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Putra Malaysia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheok Yean Chin, MSc, OMBAcC</last_name>
    <phone>+60-03-9769 2300</phone>
    <email>gs44612@student.upm.edu.my</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universiti Putra Malaysia</name>
      <address>
        <city>Serdang</city>
        <state>Selangor</state>
        <zip>43400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheok Yean Chin, MSc, OMBAcC</last_name>
      <phone>+60-03 9769 2300</phone>
      <email>gs44612@student.upm.edu.my</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Putra Malaysia</investigator_affiliation>
    <investigator_full_name>Cheok Yean Chin</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Acupuncture</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

